GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Deferred Tax

PGEN (Precigen) Deferred Tax : $-2.06 Mil (TTM As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Precigen Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Precigen's change in deferred tax for the three months ended in Sep. 2024 was $0.01 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.06 Mil.

Precigen Deferred Tax Historical Data

The historical data trend for Precigen's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Deferred Tax Chart

Precigen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.16 -0.17 -0.15 -0.48

Precigen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.35 -0.03 -1.69 0.01

Precigen Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.06 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen Deferred Tax Related Terms

Thank you for viewing the detailed overview of Precigen's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Deferred Tax
Comparable Companies
FUSN QURE KALV AVTE RPHM MGTX JANX THRD VIGL AURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
I5X:Germany
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Website
http://www.precigen.com
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Executives
Randal J Kirk director, 10 percent owner, officer: Chief Executive Officer 1881 GROVE AVENUE, RADFORD VA 24141
Jeffrey Thomas Perez officer: SVP, IP Affairs 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Jeffrey B Kindler director 35 E. 62ND ST, NEW YORK NY 10065
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari director, officer: President and CEO 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah officer: Chief Operating Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian officer: Chief Financial Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Donald P. Lehr officer: Chief Legal Officer 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro director 155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez director C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley director 9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a. 10 percent owner ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170